Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
16,005,162
-
Share change
-
+2,184,182
-
Total reported value
-
$164,194,970
-
Price per share
-
$10.29
-
Number of holders
-
59
-
Value change
-
+$26,979,833
-
Number of buys
-
28
-
Number of sells
-
40
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2018
As of 30 Sep 2018,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,005,162 shares.
The largest 10 holders included
FMR LLC, BVF INC/IL, FARALLON CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, GREAT POINT PARTNERS LLC, Pharmstandard International S.A., RENAISSANCE TECHNOLOGIES LLC, Vanguard Group Inc, DIMENSIONAL FUND ADVISORS LP, and JENNISON ASSOCIATES LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.